The Bard PowerPort implanted port catheter, manufactured by Bard Medical and its parent company BD, has become the subject of growing plaintiff-side litigation centered on polyurethane component fracture, device migration, and serious downstream injuries including cardiac complications. For law firms actively building a docket in this space, paid social acquisition on Meta platforms represents a direct channel to reach the patients most likely to have experienced — and recognized — a device failure.
MTAA works with plaintiff firms to design and deploy Facebook and Instagram campaigns that surface qualified Bard PowerPort claimants at scale. Intake is currently open, the injury profile is specific and verifiable, and the implant's brand recognition among patients who received one makes audience targeting and creative messaging unusually precise for a device tort of this type.
Litigation against Bard Medical and BD focuses on allegations that the polyurethane construction of the PowerPort catheter is prone to fracture during or after implantation, allowing device fragments to migrate through the vascular system. The injuries at the center of these claims — catheter fracture, migration, and cardiac injury — are serious, documentable through imaging and surgical records, and in the strongest cases required surgical intervention to address. That combination of a named, widely distributed implant and a discrete, medically confirmed failure mode creates a litigation landscape well-suited to structured claimant acquisition.
Because the PowerPort is an implanted device with a known manufacturer and a specific model identity, plaintiff firms can build dockets around claimants whose medical records will either confirm or rule out the core allegations relatively early in intake. That efficiency matters when evaluating the economics of a paid acquisition campaign — and it shapes how MTAA structures targeting, creative, and the qualification funnel for this tort.
Who a campaign targets
Primary target audience: Individuals who had a Bard PowerPort implanted and subsequently experienced a confirmed catheter fracture or device migration — particularly those whose condition required surgical intervention to correct.
Strongest claimant profile: Documented PowerPort implant + imaging or surgical evidence of fracture or migration + procedure required to retrieve or address the migrated fragment or damaged catheter.
Secondary / borderline profile: Individuals who experienced a device malfunction — port failure, flow issues, or other anomalies — but whose records do not yet confirm fracture or migration. These cases warrant intake review but carry more uncertainty and should be weighted accordingly in campaign economics.
Intake framing for the firm: Campaigns should be structured to drive highest volume among the fracture/migration/surgical-intervention profile, with a secondary intake path that captures borderline claimants for attorney review rather than automatic qualification.
How MTAA runs Bard PowerPort Catheter campaigns
The creative strategy for a Bard PowerPort campaign leans on the implant's name recognition and the visceral specificity of the injury. Patients who experienced a catheter fracture or were told a fragment had migrated toward their heart remember that moment — the diagnosis, the follow-up imaging, the conversation about surgery. Facebook and Instagram creative that speaks directly to that experience, using plain language about port catheters breaking or moving inside the body, will resonate with the right audience and self-select against unrelated device claims. MTAA builds ad sets around this specificity: the device name, the failure type, and the medical intervention — not generic 'medical device lawsuit' language that attracts noise.
On the audience side, Meta's health-adjacent interest and behavioral signals, combined with geographic and demographic layering consistent with the population that receives implanted port catheters — often oncology and chronic-illness patients who required long-term IV access — allow us to concentrate spend where it converts. Intake flow for this tort benefits from a short, structured pre-qualification sequence that confirms implant identity and injury type before a lead reaches your intake team, keeping cost-per-qualified-claimant in check and reducing time spent on borderline or unrelated submissions.
Pricing
Mass Tort Ad Agency runs Bard PowerPort Catheter campaigns on the same transparent model as every tort: actual Meta ad spend at cost plus a flat 15% management fee, a one-time $1,000 setup fee per tort, and $100 per signed retainer for CloudIntake qualification. No per-case markups, no lead resale, and the firm owns its ad account, pixel, creative, and claimant data.
Bard PowerPort Catheter advertising — common questions
Is the Bard PowerPort tort active enough to justify a paid Meta campaign right now?
Yes — intake is currently open and the litigation is in an active docket-building phase, which is typically the window where paid acquisition delivers the best return for plaintiff firms. Waiting until a case reaches a more advanced procedural stage usually means competing against more firms for a shrinking pool of unrepresented claimants. Running now positions your firm to accumulate cases while the field is still developing.
How does MTAA distinguish a strong Bard PowerPort lead from a borderline one at the campaign level?
The campaign and intake funnel are structured around the core qualification markers: confirmed Bard PowerPort implant, a reported fracture or migration event, and — for the strongest cases — a surgical intervention that followed. Creative messaging is written to resonate specifically with people who experienced those outcomes, which naturally filters toward the higher-value claimant profile. Borderline submissions, such as those reporting malfunction without confirmed fracture or migration, are flagged separately for attorney review rather than treated as qualified leads.
What makes this tort's creative strategy different from a general pharmaceutical or device campaign?
The Bard PowerPort has a recognized brand name among the patients who received it, and the failure mechanism — a catheter physically breaking and potentially moving toward the heart — is concrete and memorable in a way that abstract drug side effects are not. That specificity lets us write ad copy and design visuals that speak directly to a real patient experience rather than relying on broad 'you may be entitled to compensation' language. The result is higher relevance scores, lower cost per click, and better lead quality at intake.
What does the intake handoff look like for a Bard PowerPort campaign MTAA runs?
MTAA builds a pre-qualification sequence — typically a short-form flow embedded in or linked from the ad — that confirms the key identifiers: whether the person had a PowerPort specifically, whether they experienced a fracture, migration, or related complication, and whether medical intervention was required. Leads that clear those gates are delivered to your intake team with that context already captured, so the first conversation can focus on case development rather than basic eligibility screening. Borderline responses are separated and delivered with appropriate flags for your team's discretion.
Ready to run Bard PowerPort Catheter campaigns?
We build, run, and qualify Bard PowerPort Catheter claimant-acquisition campaigns end to end. Book a call and we'll walk you through the creative, audience, and intake plan.